Pharmabiz
 

NPPA fixes ceiling prices of 1 scheduled formulation of Schedule-I and retail prices of 4 formulations under DPCO, 2013

Our Bureau, MumbaiMonday, June 12, 2017, 15:45 Hrs  [IST]

NPPA has fixed/revised ceiling prices/Retail Prices of 1 scheduled formulation of Schedule-I under Drugs (Price Control) Amendment Order, 2016 under DPCO, 2013 and retail prices of 4 formulation under DPCO, 2013.

Ceiling prices of 1 scheduled formulation of Schedule-I under Drugs (Prices Control) Amendment Order, 2016 is Clotrimazole.

Retail prices of 4 formulations under DPCO, 2013 are Pacimol 10mg/ml
Infusion, Pacimol MF tablet, Ten- DC M 500 tablet and Ten - DC M 1000 tablet.

“All manufacturers of scheduled formulations, selling the branded or generic or both versions of scheduled formulations at a price higher than the ceiling price [plus local taxes as applicable] fixed and notified by the government, shall revise the prices…,” said officials while releasing the list of drugs. “We started with major drugs and products like stents and are now covering common medicines. While the price change is only 10% to 15%, the move will ensure there is no black marketing in the future.”

Officials have notified all manufacturers to maintain the maximum retail price (MRP) if it is lower than the capped price. “The manufacturers may add local taxes only if they have paid them or if it is payable to the government on the ceiling price mentioned,” said the officials.

Every retailer and dealer is expected to display the main price list and the supplementary price list, if any, as furnished by the manufacturer, for the customers to check. The officials said that in cases of overcharging, the manufacturer or retailer shall be liable to deposit the overcharged amount along with interest under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

 
[Close]